AtriCure Bundle
Who owns AtriCure today?
AtriCure, Inc. (NASDAQ: ATRC) evolved from founder-led beginnings in 2000 to broad institutional ownership as it scaled surgical ablation systems for atrial fibrillation. Market cap ran roughly between $1.8–$3.0 billion in 2024–2025, with 2023 revenue near the mid-$400 million range.
Major shareholders now include mutual funds, ETFs and index complexes, with founders and insiders holding smaller stakes; voting power is mainly institutional. See AtriCure Porter's Five Forces Analysis for product and market context.
Who Founded AtriCure?
AtriCure was co-founded in 2000 by David J. Drachman alongside a small team of cardiac-device innovators and early employees, leveraging clinical advisor relationships with cardiac surgeons; initial equity details were not publicly disclosed but reflected typical early-stage medical-device splits. Early capital combined friends-and-family and angel investors from Midwest medtech networks supporting surgical Afib solutions.
Founding Team
David J. Drachman led the founding group with early engineering and clinical collaborators focused on surgical atrial fibrillation tools.
Early Capital
Initial funding mixed friends-and-family and angel rounds tied to Midwest medtech angels rather than large catheter-focused VCs prevalent then.
Equity Practices
Founders and early hires typically had four-year vesting with one-year cliffs, standard IP assignments, and buy-sell protections on the cap table.
Dilution Through Rounds
Priced venture and strategic rounds expanded option pools and partially diluted early angels as the company pursued regulatory milestones and commercial launch.
Governance Protections
Buy-sell rights and standard investor protections helped stabilize ownership during growth financing without reported contentious recapitalizations.
Transition of Control
Control shifted gradually via financing and dilution rather than legal disputes; founders maintained a long-horizon clinical vision during scale-up.
Early ownership norms set the groundwork for later institutional interest; by public and secondary rounds, institutional investors and mutual funds became material holders, while founder and insider ownership percentages declined as part of normal venture-to-public company evolution.
Key facts about early ownership
Founders, early employees, and angels followed standard startup equity and governance practices that protected the cap table through growth.
- Founding year: 2000
- Co-founder / initial CEO: David J. Drachman
- Typical vesting: four years with a one-year cliff
- Early funding: friends-and-family plus angel investors from Midwest medtech networks
For details on revenue context and how early ownership supported product commercialization, see Revenue Streams & Business Model of AtriCure.
AtriCure SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has AtriCure’s Ownership Changed Over Time?
Key financing and public listing events from 2000–2005 set institutional oversight and an equity culture at AtriCure, while 2010s accumulation by growth-stage funds and 2020–2025 passive/active managers solidified an institutional-dominant ownership base.
| Period | Ownership Dynamics | Key Stakeholders |
|---|---|---|
| 2000–2004 | Seed and venture rounds established institutional governance; option grants aligned executives and clinicians with equity upside. | Venture capital, founders, early executives |
| 2005 (IPO) | Nasdaq listing under ticker ATRC as one-share–one-vote common; initial market cap in the low hundreds of millions to fund trials and commercialization. | Public investors, institutional IPO allocates |
| 2010s | Growth-stage healthcare funds and small/mid-cap generalists increased stakes; founder/early-exec holdings diluted by option vesting and secondary sales. | Healthcare-focused institutions, SMID-cap managers |
| 2020–2025 | U.S. institutions dominate; aggregate institutional ownership commonly >95%, insider ownership in low single digits; no corporate parent or controlling family. | Index funds (Vanguard, BlackRock), active managers (Wasatch, William Blair, Fidelity, T. Rowe Price) |
Institutional concentration and a dispersed insider base have shaped governance and strategy, with investors prioritizing procedure growth, margin expansion, and evidence-led clinical milestones; see Mission, Vision & Core Values of AtriCure for company context.
AtriCure ownership snapshot (2024–2025)
Top holders mix passive index complexes and active healthcare/growth managers; insiders hold low single digits, institutions exceed 95%.
- Largest single institutional holder typically mid-single to low-double-digit percent
- Other top institutional holders typically low- to mid-single-digit percentages
- No controlling shareholder; governance responsive to broad institutional expectations
- Ownership trends visible in 13F filings, proxy statements and quarterly ownership disclosures
AtriCure PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on AtriCure’s Board?
The AtriCure board in 2024–2025 comprises the CEO in an executive seat and a majority-independent slate of directors with medtech operating experience, clinicians, regulatory and clinical affairs expertise, and financial governance backgrounds; committee chairs for audit, compensation and nominating/governance are independent.
| Director | Role / Background | Independence & Committees |
|---|---|---|
| CEO | Executive leadership; cardiac device strategy | Executive seat; not independent |
| Independent Director A | Former medtech operator; product commercialization | Independent; Chair, Compensation Committee |
| Independent Director B | Cardiac electrophysiologist; clinical advisory experience | Independent; Governance Committee member |
| Independent Director C | Regulatory and clinical affairs leader | Independent; Chair, Nominating/Governance Committee |
| Independent Director D | Public-company CFO / financial expert | Independent; Chair, Audit Committee |
AtriCure operates a one-share-one-vote structure with a single class of common stock, no founder or golden shares, and no public record of dual-class conversions or special voting rights; voting power is diffuse, with institutional investors collectively influential but without designated board seats.
Board composition and voting dynamics
The board is majority independent and aligned with medtech governance norms; routine proxy seasons have featured standard say-on-pay votes and director re-elections without sustained activist contests.
- One-share-one-vote common stock; no dual-class or golden-share mechanisms
- Committee leadership for audit, compensation and nominating/governance is independent
- Large institutional shareholders engage through outreach and proxy voting but hold no designated seats
- For ownership details and context, see Competitors Landscape of AtriCure
AtriCure Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped AtriCure’s Ownership Landscape?
Recent ownership trends for AtriCure show rising institutional concentration with passive index effects increasing float; insider stakes have declined modestly due to option exercises and leadership transitions through 2021–2025.
| Period | Key Ownership Trend | Quantitative Notes |
|---|---|---|
| 2021–2023 | Accelerated institutional accumulation as surgical ablation and LAA adoption drove revenue; Russell/index rebalances boosted passive holdings | Institutional ownership rose, passive ownership bump from rebalances; insider ownership down via option exercises |
| 2023–2025 | High institutional concentration with turnover among top holders; capital allocation prioritized R&D and tuck‑ins over buybacks | Institutional concentration remained >90%; no large buyback programs; episodic secondary offerings only |
Top‑holder turnover reflected SMID‑cap medtech performance cycles: some growth funds trimmed in 2022–2023, re-entered in 2024 as volumes normalized; management hires from larger medtechs altered governance breadth but not control.
Institutional concentration
Institutional ownership has been the dominant force, exceeding 90% by 2025 in filings and 13F snapshots, reflecting mutual funds, ETFs and asset managers as primary shareholders.
Insider ownership trend
Insider ownership trended lower due to option exercises and tenure changes; CEO and executive holdings remain meaningful but not controlling, per proxy disclosures.
Capital allocation
Company prioritized R&D, evidence generation, and tuck‑in technology investments; secondary offerings historically funded growth without creating a control bloc.
Outlook for ownership shifts
Analysts in 2024–2025 cite durable mid‑teens revenue growth potential and operating leverage, suggesting a stable, diversified shareholder base driven by index flows and performance‑based active reallocations; no signals of privatization or dual‑class moves. Read more on the Growth Strategy of AtriCure.
AtriCure Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of AtriCure Company?
- What is Competitive Landscape of AtriCure Company?
- What is Growth Strategy and Future Prospects of AtriCure Company?
- How Does AtriCure Company Work?
- What is Sales and Marketing Strategy of AtriCure Company?
- What are Mission Vision & Core Values of AtriCure Company?
- What is Customer Demographics and Target Market of AtriCure Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.